NAD bounces Notox to FTC
This article was originally published in The Tan Sheet
Executive Summary
Claims for A.D. Pharma's alcohol-intoxication reducer have been referred to the Federal Trade Commission after the firm failed to make a "bona fide good faith attempt to bring its advertising into compliance with NAD's recommendations," the Council of Better Business Bureaus division says in an Aug. 19 release. Notox was the subject of a NAD inquiry in the spring (1"The Tan Sheet" May 3, 2004, In Brief). At issue were claims that clinical studies indicate the Panax ginseng/citrus reticulate supplement "combats the effects of alcohol intoxication." The watchdog group notes that the television commercial NAD objected to has been permanently discontinued...
You may also be interested in...
Notox gets buzzed by NAD
Statements that "clinical test results show that Notox...combats the effects of alcohol intoxication" should be modified, the National Advertising Division tells A.D. Pharma following a recent review. Implied and explicit claims on TV, radio, and print ads and testimonials for the Panax ginseng/citrus reticulate supplement, found during routine monitoring, are not supported by a trial in 10 male subjects, the watchdog group adds. NAD also was troubled by claims that could lead consumers to believe that "Notox allows product users to drink and drive." A.D. Pharma said it modified the television spot prior to NAD's inquiry, and plans on revising its website...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.